#1 Clinical Trials Search in Europe

Acute lymphocytic leukaemia recurrent – Diagnostics

Go back

Finding out if acute lymphocytic leukemia has returned after treatment requires careful testing and monitoring, as early detection of relapse can make a significant difference in choosing the right next steps for care.

Introduction: Who Should Undergo Diagnostics

When someone has already been treated for acute lymphocytic leukemia and achieved remission, the question of whether the disease has come back can feel overwhelming. Recurrent acute lymphocytic leukemia, which means the cancer has returned after a period of improvement, occurs in about 15 to 20 percent of children who were previously treated for this condition.[5][15] Adults face different challenges, as their bodies may respond differently to both the initial treatment and any return of the disease.

Anyone who has been treated for acute lymphocytic leukemia should stay alert to changes in their body that might signal a problem. This includes both children and adults. If you notice symptoms similar to those you experienced when first diagnosed, it is important to see your doctor right away. These warning signs can include unusual tiredness that doesn’t improve with rest, frequent infections that seem harder to shake off, unexplained bruising or bleeding, or lumps that appear under the skin or in the neck, armpits, or groin area.[1][2]

People who completed treatment should also attend all scheduled follow-up appointments, even if they feel perfectly healthy. Doctors recommend ongoing monitoring because sometimes leukemia can return without causing noticeable symptoms at first. Regular check-ups allow healthcare providers to catch any problems early, when they might be easier to address. This proactive approach is especially important during the first few years after treatment, when the risk of recurrence tends to be highest.[9]

Parents of children who have been treated for acute lymphocytic leukemia should watch for changes in their child’s energy level, appetite, or behavior. Children might not always be able to express how they feel, so adults need to pay attention to subtle shifts. If a child seems more tired than usual, develops frequent fevers, or complains of bone pain, these could be important signs that warrant medical attention.

⚠️ Important
Between 15 and 20 percent of children treated for acute lymphocytic leukemia experience a relapse, meaning the disease returns after treatment. Most of these recurrences happen within one to two years after the initial treatment ended, which is why close monitoring during this period is so critical for catching any problems early.[5][9][15]

Diagnostic Methods

When doctors suspect that acute lymphocytic leukemia might have returned, they use several tests to confirm whether cancer cells are present again. The diagnostic process for recurrent disease is similar to the testing done at the time of initial diagnosis, but doctors may also use additional information from your previous treatment history to guide their decisions.

Blood Tests

The first step in diagnosing recurrent acute lymphocytic leukemia usually involves blood tests. A complete blood count, often called a CBC, measures the number of different types of cells in your blood, including white blood cells, red blood cells, and platelets. When leukemia returns, the CBC often shows abnormal patterns. You might have too many or too few white blood cells, not enough red blood cells causing anemia (low blood oxygen levels), or too few platelets that help your blood clot.[3][6]

Blood tests might also reveal the presence of blast cells, which are immature blood cells that normally stay in the bone marrow. When these cells appear in the bloodstream, it can be a sign that leukemia has returned. A blood smear involves looking at your blood under a microscope, which allows laboratory specialists to examine the size, shape, and characteristics of individual cells in detail.[14][22]

Beyond the basic blood count, doctors often order blood chemistry tests to check how well your organs are functioning. These tests look at kidney and liver function, as well as the levels of various minerals and proteins in your blood. This information helps doctors understand how your body is handling the disease and whether other organs might be affected.

Bone Marrow Tests

A bone marrow examination is considered the most reliable way to diagnose recurrent acute lymphocytic leukemia. This test involves removing a small sample of bone marrow, usually from the hip bone, to look for leukemia cells. There are two types of bone marrow tests that are often done together: bone marrow aspiration and bone marrow biopsy.[14][22]

During a bone marrow aspiration, a doctor uses a thin, hollow needle to withdraw a small amount of liquid bone marrow. This liquid sample contains cells that can be examined under a microscope. A bone marrow biopsy removes a tiny piece of solid bone tissue along with the marrow inside it. Both samples are sent to a laboratory where specialists analyze them to look for cancer cells and determine their characteristics.

The bone marrow test provides crucial information beyond just confirming whether leukemia has returned. Laboratory doctors classify the cancer cells based on their size, shape, and genetic features. They can determine whether the leukemia cells developed from B lymphocytes or T lymphocytes, which are two different types of white blood cells. This classification matters because different types of acute lymphocytic leukemia may respond better to different treatments.[14][22]

The procedure for obtaining bone marrow samples can feel uncomfortable, but doctors typically use local anesthesia to numb the area and sometimes provide sedation to help patients relax. The discomfort usually lasts only a few minutes, and most people can return to their normal activities within a day or two.

Imaging Tests

Imaging tests create pictures of the inside of your body and help doctors see whether leukemia cells have spread to other organs or tissues. Several different imaging techniques might be used when checking for recurrent acute lymphocytic leukemia.

A chest X-ray is often one of the first imaging tests ordered. This simple test can show whether lymph nodes in the chest have become enlarged or if there are other changes in the lungs or chest area. Some patients with a specific type of acute lymphocytic leukemia called T-cell ALL may develop tumors behind the breastbone, and a chest X-ray can help identify these.[9]

Computed tomography, or CT scans, provide more detailed cross-sectional images of the body than regular X-rays. A CT scan can help doctors examine the chest, abdomen, and pelvis to look for enlarged lymph nodes, an enlarged liver or spleen, or other signs that leukemia has spread. During a CT scan, you lie still on a table that moves through a large, doughnut-shaped machine that takes multiple X-ray pictures from different angles.[2][9]

Magnetic resonance imaging, known as MRI, uses powerful magnets and radio waves instead of X-rays to create detailed images of soft tissues. An MRI is particularly useful for looking at the brain and spinal cord if doctors are concerned that leukemia cells might have spread to the central nervous system. This test takes longer than a CT scan, often 30 to 60 minutes, and you need to lie very still inside a tube-like machine that can feel confining.[2][9]

Positron emission tomography, or PET scans, involve injecting a small amount of radioactive sugar into your bloodstream. Cancer cells tend to absorb more of this sugar than normal cells because they grow and divide more rapidly. A special camera then detects where the radioactive material has concentrated in your body, highlighting areas where cancer might be present. PET scans are sometimes combined with CT scans to provide both metabolic and anatomical information at the same time.[2]

Ultrasound tests use sound waves to create images of organs and tissues. A pelvic ultrasound or abdominal ultrasound can show whether the liver, spleen, or lymph nodes in the abdomen have become enlarged. This test is painless and doesn’t involve any radiation exposure, making it particularly useful for repeated examinations.

Spinal Tap

Acute lymphocytic leukemia has a tendency to spread to the fluid that surrounds the brain and spinal cord, called cerebrospinal fluid or CSF. To check for leukemia cells in this fluid, doctors perform a procedure called a lumbar puncture or spinal tap. During this test, you typically lie on your side with your knees drawn up to your chest, or you might sit and lean forward. A doctor inserts a thin needle between the bones of your lower spine to collect a small sample of cerebrospinal fluid.[9][14][22]

The collected fluid is sent to a laboratory where specialists examine it under a microscope to look for leukemia cells. They also measure protein and glucose levels in the fluid, which can provide additional information about whether the central nervous system is affected. Finding leukemia cells in the cerebrospinal fluid is important because it affects treatment decisions and indicates that special therapies targeting the central nervous system may be needed.

Most people experience only mild discomfort during a lumbar puncture, especially when local anesthesia is used to numb the area. Some people develop a headache after the procedure, which usually improves with rest and fluids. Doctors typically recommend lying flat for a period after the test to reduce the risk of headache.

Genetic and Molecular Testing

Modern diagnosis of recurrent acute lymphocytic leukemia involves looking at the genetic and molecular characteristics of cancer cells. These tests examine the DNA and chromosomes inside leukemia cells to identify specific changes or abnormalities. Different genetic changes can affect how aggressive the leukemia is and how well it might respond to various treatments.[14][22]

Flow cytometry is a laboratory technique that analyzes the characteristics of cells by passing them one by one through a laser beam. This test can identify specific proteins on the surface of cells, which helps classify the exact type of leukemia and distinguish cancer cells from normal cells. Flow cytometry is particularly useful because it can detect small numbers of leukemia cells, sometimes even when other tests appear normal.

Doctors also look for specific chromosome changes in leukemia cells. Some people with acute lymphocytic leukemia have what’s called the Philadelphia chromosome, which is an abnormal chromosome created when two other chromosomes swap pieces. Knowing whether this chromosome is present helps doctors choose the most appropriate treatment approach.

Physical Examination

A thorough physical examination remains an essential part of diagnosing recurrent acute lymphocytic leukemia. During the exam, your doctor will feel for enlarged lymph nodes in your neck, armpits, and groin. They will also press gently on your abdomen to check whether your liver or spleen has become enlarged, which can happen when leukemia cells accumulate in these organs.[2][4]

Your doctor will look at your skin for signs of bleeding under the surface, such as small red or purple spots called petechiae, or larger bruises. They’ll check your eyes, mouth, and throat for any abnormalities. The physical exam also includes listening to your heart and lungs and checking for signs of infection or other complications.

Beyond the physical findings, your doctor will ask detailed questions about your symptoms and medical history. They want to know how long you’ve been experiencing symptoms, how severe they are, and whether anything makes them better or worse. Information about your previous treatment, including which drugs you received and how well you responded, helps guide decisions about additional testing and future treatment options.

Diagnostics for Clinical Trial Qualification

When someone’s acute lymphocytic leukemia returns after treatment, participating in a clinical trial might be one option to consider. Clinical trials test new treatments or new combinations of existing treatments to find better ways to fight cancer. However, not everyone qualifies for every clinical trial, and specific diagnostic tests help determine whether you meet the criteria for participation.

Standard Eligibility Testing

Before enrolling in a clinical trial for recurrent acute lymphocytic leukemia, you’ll typically need to undergo comprehensive diagnostic testing. These tests serve two purposes: they confirm that you have the specific type and stage of disease that the trial is studying, and they make sure your body is healthy enough to tolerate the experimental treatment being tested.

Blood tests are almost always required for clinical trial screening. Researchers need to confirm that you have recurrent disease by showing the presence of leukemia cells in your blood or bone marrow. They also need baseline measurements of your blood cell counts, organ function, and overall health status. These baseline values become the starting point for comparing how you respond to the trial treatment.[2][9]

A fresh bone marrow biopsy is typically necessary, even if you had one recently for diagnosis. Clinical trials often require specific tests on bone marrow samples to look for particular genetic markers or characteristics in the leukemia cells. The trial might be testing a treatment that targets a specific genetic change, so proving that your leukemia cells have that change is essential for enrollment.

Specialized Molecular Testing

Many clinical trials for recurrent acute lymphocytic leukemia focus on targeted therapies that work against specific molecular features of cancer cells. This means you may need specialized testing to identify whether your leukemia has the characteristics that the experimental treatment is designed to attack.

For example, some trials test drugs that target leukemia cells with certain surface proteins. Flow cytometry or other immunological tests can identify these proteins. Other trials might require testing for specific gene mutations or chromosome abnormalities. These molecular tests help match patients to the clinical trials most likely to benefit them.[14][22]

Organ Function Assessment

Clinical trials have strict requirements about organ function because experimental treatments can sometimes put stress on the heart, kidneys, liver, or other organs. Before enrolling, you’ll likely need tests to measure how well these organs are working.

An electrocardiogram (ECG or EKG) records the electrical activity of your heart and can detect rhythm problems or other heart issues. An echocardiogram, which is an ultrasound of the heart, provides detailed information about how well your heart is pumping blood. These heart tests are particularly important if the trial involves drugs that might affect heart function.[2]

Blood tests measuring creatinine and blood urea nitrogen (BUN) show how well your kidneys are filtering waste from your blood. Liver function tests measure enzymes and proteins that indicate whether your liver is working properly. If these values are outside certain ranges, you might not be eligible for trials testing drugs that are processed by these organs.

Assessment of Disease Spread

Clinical trials often have specific criteria about how much the leukemia has spread and where it is located. You may need imaging tests like CT scans, MRI scans, or PET scans to map out the extent of disease in your body. A lumbar puncture might be required to determine whether leukemia cells have spread to your central nervous system.[9][14]

Some trials only accept patients whose disease is confined to certain areas, while others specifically look for patients whose leukemia has spread more extensively. Understanding exactly where the cancer is located helps researchers determine whether you match the trial’s enrollment criteria.

Performance Status Evaluation

Clinical trials assess your overall physical condition using something called performance status. This is a measure of how well you can carry out daily activities and how much the cancer is affecting your quality of life. Doctors use standardized scales to rate your performance status, considering factors like whether you can care for yourself, how much time you spend in bed or a chair, and whether you can work or do household tasks.

Your performance status helps researchers determine whether you’re healthy enough to participate in the trial safely. Some trials only accept patients with better performance status because the experimental treatments might be quite intensive. Other trials specifically study patients with poorer performance status to find treatments that work for people who are more debilitated by their disease.

⚠️ Important
Clinical trials for recurrent acute lymphocytic leukemia often test innovative approaches like CAR T-cell therapy or new targeted drugs. These trials require extensive diagnostic testing not just to confirm you’re eligible, but also to establish baseline measurements that allow researchers to accurately track how well the experimental treatment is working. Your willingness to undergo these tests contributes to medical knowledge that might help future patients.[10][11]

Previous Treatment Documentation

For clinical trials studying recurrent disease, detailed records of your previous treatment are crucial. Researchers need to know exactly which chemotherapy drugs you received, what doses you took, how long your treatment lasted, and how well you responded. They also want to know how long you remained in remission before the leukemia returned.

This information affects trial eligibility in several ways. Some trials only accept patients who have tried certain standard treatments first. Others might exclude patients who previously received specific drugs that could interfere with the experimental treatment. The timing of your relapse also matters; some trials focus on people whose leukemia came back quickly after treatment, while others study people who had longer remissions.

Monitoring During Trial Participation

Once enrolled in a clinical trial, you’ll undergo regular diagnostic testing throughout your participation. These repeated tests track how your leukemia is responding to the experimental treatment and watch for any side effects or complications. The frequency and type of testing varies depending on the trial, but typically includes regular blood tests, periodic bone marrow examinations, and imaging studies at specific time points.

This ongoing monitoring generates valuable data that helps researchers understand whether the new treatment is effective and safe. Even if the treatment doesn’t work as well as hoped for you personally, the information gathered from your participation helps advance medical knowledge and might lead to breakthroughs that benefit others in the future.

Prognosis and Survival Rate

Prognosis

The outlook for someone whose acute lymphocytic leukemia has returned depends on several important factors. One key consideration is when the relapse occurred. People whose leukemia comes back after a longer period of remission generally have a better prognosis than those whose disease returns quickly after completing treatment. The location of the relapse also matters; for example, if leukemia cells are found only in the bone marrow rather than having spread to the central nervous system or other organs, the outlook may be somewhat better.[10][13]

Age plays a significant role in prognosis. Children with recurrent acute lymphocytic leukemia tend to have better outcomes than adults. The specific type of leukemia cells involved, whether B-cell or T-cell, can also affect the outlook. Additionally, how well the person’s body tolerated previous treatment and their overall health status at the time of relapse influence what can be expected going forward.[9]

Genetic characteristics of the leukemia cells provide important prognostic information. Certain genetic changes make the disease more aggressive and harder to treat, while others may indicate a better chance of responding to specific therapies. Modern treatments, including newer immunotherapies and targeted drugs, have improved outcomes for some patients with recurrent disease, though results vary considerably from person to person.[10][11]

Survival rate

Survival rates for recurrent acute lymphocytic leukemia vary significantly based on multiple factors. For children with relapsed disease, approximately 75 percent remain cancer-free after five years with appropriate treatment. However, this represents children who respond well to therapy for the relapse. Among adults with recurrent disease, the outlook is generally more challenging, with around 60 percent remaining cancer-free after three years.[9]

It’s important to understand that these statistics represent averages across many patients and may not predict any individual person’s outcome. Some people with recurrent acute lymphocytic leukemia achieve long-term remission or even cure with aggressive treatment, including stem cell transplants or newer immunotherapies. Treatment can cure up to 80 percent of children with relapsed disease, but the success rate is typically less than 50 percent in adults.[9]

Around one-third of patients experience another relapse within one to two years after treatment for recurrent disease. This statistic underscores why close monitoring after treatment remains so important. The development of new therapies, particularly CAR T-cell therapy and other immunotherapy approaches, continues to improve outcomes for some patients whose disease returns, though these treatments are not appropriate or successful for everyone.[9][10][11]

Ongoing Clinical Trials on Acute lymphocytic leukaemia recurrent

  • A study testing AZD3632 alone or with other anticancer drugs in adults with acute leukemia or myelodysplastic syndromes with HOX gene overexpression

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Germany Italy

  • Study of DDCART-CD19 cells with cyclophosphamide and fludarabine for children and young adults (up to 39 years) with recurrent acute leukemia after stem cell transplant

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

References

https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/symptoms-causes/syc-20369077

https://my.clevelandclinic.org/health/diseases/21564-acute-lymphocytic-leukemia

https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq

https://www.ncbi.nlm.nih.gov/books/NBK459149/

https://www.dana-farber.org/cancer-care/types/relapsed-childhood-acute-lymphoblastic-leukemia

https://medlineplus.gov/acutelymphocyticleukemia.html

https://www.chop.edu/conditions-diseases/acute-lymphoblastic-leukemia-all

https://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all

https://leukemiarf.org/leukemia/acute-lymphoblastic-leukemia/t-cell-lymphoblastic-leukemia/

https://cancer.ca/en/cancer-information/cancer-types/acute-lymphoblastic-leukemia-all/treatment/relapsed-or-refractory

https://pubmed.ncbi.nlm.nih.gov/38916714/

https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq

https://bloodcancer.org.uk/understanding-blood-cancer/leukaemia/acute-lymphoblastic-leukaemia/all-treatments-side-effects/treatment-relapsed-all/

https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/diagnosis-treatment/drc-20369083

https://www.dana-farber.org/cancer-care/types/relapsed-childhood-acute-lymphoblastic-leukemia

https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating/typical-treatment.html

https://my.clevelandclinic.org/health/diseases/21564-acute-lymphocytic-leukemia

https://www.healthline.com/health/cll/balancing-daily-life

https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/after-treatment/follow-up.html

https://my.clevelandclinic.org/health/diseases/21564-acute-lymphocytic-leukemia

https://www.cancercare.org/publications/357-treatment_update_chronic_lymphocytic_leukemia

https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/diagnosis-treatment/drc-20369083

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

More information about
Acute lymphocytic leukaemia recurrent:

FAQ

How do doctors tell the difference between relapsed acute lymphocytic leukemia and a new cancer?

Doctors compare the genetic and molecular characteristics of cancer cells found during suspected relapse with the features of cells from your original diagnosis. If the cells have the same genetic fingerprint, it’s a relapse of the same leukemia. The laboratory analysis from your original bone marrow biopsy serves as a reference point for this comparison, allowing specialists to determine whether leukemia cells truly returned or whether a completely different cancer developed.

Can blood tests alone confirm that acute lymphocytic leukemia has come back?

Blood tests can strongly suggest that leukemia has returned, especially if they show abnormal white blood cell counts or the presence of blast cells in the bloodstream. However, doctors typically need a bone marrow biopsy to definitively confirm relapse because it provides the most accurate assessment of disease in the bone marrow where leukemia originates. Blood tests serve as an important screening tool, but the bone marrow examination remains the gold standard for diagnosis.

Why do doctors check the cerebrospinal fluid when diagnosing recurrent leukemia?

Acute lymphocytic leukemia has a tendency to spread to the fluid surrounding the brain and spinal cord, called the central nervous system. A spinal tap allows doctors to collect cerebrospinal fluid and examine it for leukemia cells. Finding cancer cells in this fluid is important because it changes treatment decisions; if leukemia has spread to the central nervous system, additional therapies targeting that area become necessary to achieve the best possible outcome.

How often should someone have follow-up tests after completing treatment for acute lymphocytic leukemia?

The frequency of follow-up testing varies depending on individual circumstances, but monitoring is typically most intensive during the first two years after treatment ends because this is when most relapses occur. Initially, you might have blood tests and physical examinations every one to three months. As time passes without signs of disease, the intervals between check-ups gradually lengthen. Your doctor creates a personalized monitoring schedule based on factors like your age, type of leukemia, and how you responded to initial treatment.

What makes someone eligible for a clinical trial for recurrent acute lymphocytic leukemia?

Eligibility for clinical trials depends on many factors specific to each trial. Generally, you need confirmed recurrent disease documented by bone marrow biopsy and blood tests. Your organs, especially your heart, kidneys, and liver, must function well enough to handle the experimental treatment. Trials often require specific genetic characteristics in your leukemia cells that match what the treatment targets. Your overall physical condition, measured by performance status, matters too, as does your treatment history and how long you remained in remission before relapse.

🎯 Key takeaways

  • • Relapsed acute lymphocytic leukemia requires many of the same diagnostic tests used at initial diagnosis, including blood tests, bone marrow biopsy, and imaging studies to map where the disease has spread.
  • • About 15 to 20 percent of children treated for acute lymphocytic leukemia experience relapse, with most recurrences happening within one to two years after completing treatment.
  • • Bone marrow biopsy remains the gold standard for confirming recurrent leukemia because it provides the most accurate assessment of disease and allows detailed genetic and molecular analysis of cancer cells.
  • • Checking cerebrospinal fluid through a spinal tap is essential because acute lymphocytic leukemia commonly spreads to the brain and spinal cord, requiring different treatment approaches if detected.
  • • Clinical trial participation requires extensive diagnostic testing to confirm eligibility, including specialized molecular tests that identify specific characteristics in leukemia cells that the experimental treatment targets.
  • • The timing of relapse provides important information about prognosis, with disease returning after longer remissions generally responding better to treatment than early relapses.
  • • Modern diagnostic techniques like flow cytometry can detect very small numbers of leukemia cells, sometimes identifying disease recurrence before symptoms develop or other tests show abnormalities.
  • • Survival rates for recurrent acute lymphocytic leukemia vary significantly based on age, timing of relapse, and disease characteristics, with children generally having better outcomes than adults.

Connected medications: